Nomura is a buyer of Incyte and Pharmacyclics into ASCO meetings Nomura is a buyer of Incyte (INCY) and Pharmacyclics (PCYC) following the ASCO abstract releases. The firm expects 50mg dose data on June 2 to meet investor expectations and for shares to recover. For Pharmacyclics, the analyst expects investor focus to be on negativity rates of Phase I/II trial of competitor ABT-199 + Rituxan and Imbruvica RESONATE Phase III data on June 3.
Incyte shares poised to advance further, says Argus Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.